Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
- Company highlights new preclinical data for wholly-owned and partnered programs following prioritization of in vivo gene editing portfolio - Expands portfolio with PBGENE-PMM as a potentially curative treatment for primary mitochondrial myopathy - Virtual R&D Day featuring key opinion leaders and
Precision BioSciences to Attend and Present at Upcoming September Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 6, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that members of management will participate in the following investor conferences in
Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 31, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced that it will host its in vivo gene editing R&D Day on Tuesday, September 12, 2023 from 9:00-11:30 AM ET .
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
- Precision Eligible to Receive up to $227 Million in Upfront Economics and Milestone Payments for Azer-Cel in Addition to Double-Digit Royalties on Sales - Imugene to Assume Control of Precision’s Cell Therapy Infrastructure in Pursuit of Biologics License Application for Azer-Cel in LBCL Patients
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
- FDA Advice Provides Clarity on Future Development for Lead CAR T Program Candidate Azer-Cel; CAR T Partnering Discussions Ongoing - Presented Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy and Chronic Hepatitis B - Company plans to host In Vivo Gene
Precision BioSciences to Report Second Quarter Results on August 4, 2023
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 1, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it will publish financial results for the second quarter 2023
Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 27, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it has received final meeting minutes from its recent Type B
Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023
- High antiviral activity with substantial and durable reductions in hepatitis B serum antigen and covalently closed circular DNA in preclinical studies of PBGENE-HBV - Supports continued PBGENE-HBV development and planned submission of CTA/IND application DURHAM, N.C. --(BUSINESS WIRE)--Jun.
Precision BioSciences to Present at Upcoming June Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 5, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS ® -based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that members of management will participate in the following
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T Related Adverse Events Were Observed Azer-Cel Achieved 83% Overall Response Rate (ORR), 61% Complete
Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023
DURHAM, N.C. --(BUSINESS WIRE)--May 25, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will share an update on its allogeneic CAR T programs
Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day
DURHAM, N.C. --(BUSINESS WIRE)--May 24, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will participate in the Stifel Genetic Medicines Day
Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting
Late-breaking, oral presentation highlights ability of ARCUS gene editing approach to achieve large gene excisions enabling significant functional muscle improvement in preclinical study DURHAM, N.C. --(BUSINESS WIRE)--May 19, 2023-- Precision BioSciences, Inc.
Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting
Late-Breaking Abstract Demonstrates Capabilities of ARCUS for Large Gene Excision In Vivo DURHAM, N.C. --(BUSINESS WIRE)--May 12, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing